PDX MODELS IN CLINICAL ONCOLOGY AND CANCER PRECISION MEDICINE

3-5 OCTOBER 2016

Seminar-Hotel Rigi am See Weggis

Switzerland

Scientific ProgrammeEach speaker in the programme will be careful to allow enough time for discussion after her/his presentation (at least 5 minutes). Short talks are 10 minutes long, with 7-8 minutes presentation and 2-3 minutes for questions; they will be presented as posters as well, to allow more discussion.

Sponsored by

MONDAY, OCTOBER 3

15:00-16:00 Registration & Coffee - Setup of Poster Session 1

16:00-16:05 Opening 5’ Jos Jonkers (NKI, Amsterdam, The Netherlands) 16:05-17:30 Session 1 - Development of subcutaneous PDX models Chair : Els Hermans (TRACE platform, KU Leuven, Belgium)

16:05 Els Hermans 25’ What does it take to build and manage a general Patient-Derived Tumor Xenograft platform in translational cancer research : the experience of Trace

16:30 Andrea Bertotti 25’ (University of Torino - Department of Oncology, Italy) Data management for living biobanks : how to deal with dynamic and heterogeneous information

16:55 Sergio Roman-Roman 25’ (Institut Curie, Paris, France) Establishing a PDX collection for rare tumour types - The case of uveal melanoma

17:20 Selected short talk : Stefano Cairo 10’ (XenTech, Evry, France) Pediatric liver cancer PDX : a preclinical pipeline to identify new treatments for relapsing hepatoblastoma

17:30-17:45 Break

17:45-19:20 Session 2 - Next-Generation PDX Models & Technologies Chair : Rob Clarke (University of Manchester, UK)

17:45 Rob Clarke 10’ Introduction to the session

17:55 Kris Frese 25’ (CRUK Manchester Institute, UK) Circulating Tumour Cell-derived explants – a new preclinical platform for studying Small Cell Lung Cancer

18:20 Arianna Fumagalli 25’ (Hubrecht Institute and UMC Utrecht, The Netherlands) In vivo dissection of the colorectal cancer adenoma-carcinoma sequence by orthotopic transplantion of engineered tumor organoids

18:45 Alberto Villanueva (ICO-IDIBELL and Xenopat, Barcelona, Spain) 25’ Orthoxenografts as tools for drug development and real-time personalized oncologic treatments

19:10 Selected short talk : Sebastian Brabetz 10’ (German Cancer Research Center (DKFZ), Heidelberg, Germany) Molecular characterisation of orthotopic patient-derived xenograft models of pediatric brain tumours

19:30-21:00 Dinner

21:00-22:30 Poster Session 1 with free drinks

TUESDAY, OCTOBER 4

7 :30-9 :00 Registration & Breakfast

9 :00-10 :30 Session 3 : Modelling the human immune system Chairs : Dominique Vanhecke (Ludwig Institute for Cancer Research at the University of Lausanne) & Joaquín Arribas (Vall d'Hebron Institute of Oncology)

9 :00 Dominique Vanhecke & Joaquín Arribas 25’ Introduction to current state of the art

9 :25 Ralph Gareus (The Jackson Laboratory) 25’ Patient-derived tumor xenografts in humanized NSG-SGM3 mice : a new immuno-oncology platform

9 :50 Johannes Sam 25’ (Roche Innovation Center Zürich) Humanised mouse models for drug discovery

10 :15 Selected short talk : Philippe De La Rochère 10’ (Institut Curie, Paris, France) Development of new humanized mouse model to study immunotherapies

10 :30-11 :00 Coffee break & Exhibition - End of poster Session 1

11 :00-12 :05 Session 4 : Modelling Cancer Phenotypes Chair : Sergio Roman-Roman (Institut Curie, Paris, France)

11 :00 Sergio Roman-Roman 15’ Introduction to the session

11 :15 Oscar Rueda 25’ (CRUK Manchester Institute, UK) Modelling heterogeneity in breast cancer PDTX models

11 :40 Elisabetta Marangoni 25’ (Institut Curie, Paris, France) Establishment and characterization of residual breast cancer patient-derived xenografts resistant to neo-adjuvant therapy

12 :15-14 :00 Lunch & Exhibition - Setup of Poster Session 2

14 :00-15 :00 Session 4 : Modelling Cancer Phenotypes - To be continued Chair : Sergio Roman-Roman

14 :00 Kristel Kemper 25’ (NKI, Amsterdam, The Netherlands) BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts

14 :25 Héctor G. Palmer 25’ (Vall d'Hebron Institute of Oncology, Barcelona, Spain) Understanding cancer cell dormancy - Strategies to eliminate the hidden seeds of a future relapse

14 :50 Selected short talk : Maria Apicella 10’ (Candiolo Cancer Institute IRCCS, University of Torino, Italy) Dual anti-MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort

Sponsored by

12

15 :00-16 :15 Session 5 : PDX derived tumour cells towards therapeutic testing Chairs : Eva Gonzalez-Suarez (Bellvitge Biomedical Research Institute IDIBELL, Barcelona, Spain) & Silvia Giordano (University of Torino-IRCC, Italy)

15 :00 Eva Gonzalez-Suarez & Silvia Giordano 15’ Introduction to the session

15 :15 Alejandra Bruna 25’ (CRUK Cambridge Institute, UK) Derivation of a pharmacogenomic platform for predicting drug responses in breast cancer

15 :40 Hayley Francies 25’ (Wellcome Trust Sanger Institute, Hinxton, UK) Towards the next-generation of cancer cell lines : derivation of an organoid biobank

16 :05 Selected short talk : Clare Dempsey 10’ (Institute of Cancer Sciences, University of Manchester, UK)

16 :15-16 :45 Coffee break & Exhibition - Setup of Poster Session 2

16 :45-18 :15 Parallel Round Tables : Meet the Experts - Breast cancer models (Chairs : Elisabetta Marangoni, Denis Alférez) - Colorectal cancer models (Chairs : Virginie Dangles-Marie, Andrea Bertotti) - Humanized models (Chairs : Dominique Vanhecke & Joaquín Arribas) - Bioinformatics (Chair : Enzo Medico)

18 :45-21 :00 Gala Dinner

21 :00-22 :30 Poster Session 2 with free drinks

13

WEDNESDAY, OCTOBER 5

7 :30-9 :00 Breakfast

9 :00-10 :30 Session 6 : PDX Strategies to inform clinical decision-making - What do we expect ? Chairs : Mohamed Bentires-Alj (University of Basel / University Hospital Basel, Basel, Switzerland) & Steven de Jong (UMCG, Groningen, The Netherlands)

9 :00 Momo Bentires-Alj & Steven de Jong 10’ Introduction to the session

9 :10 Mike Lewis 30’ (Baylor College of Medicine, Houston, TX, USA) Patient-derived Xenografts As “Avatars” In Translational Breast Cancer Research

9 :40 Stephane Ferretti 25’ (Novartis Institutes for Biomedical Research, Basel, Switzerland) Large scale PDX clinical trial to predict clinical trial drug response

10 :05 Angela M. Davies (Champions Oncology, Hackensack, NJ, USA) 25’ Patient-derived xenografts effectively capture patient clinical responses to oncology therapy

10 :30 Selected short talk : Violeta Serra 10’ (Vall d'Hebron Institute of Oncology, Barcelona, Spain) Co-clinical trial of olaparib in breast and ovarian patient-derived tumor xenografts (PDX) enables the identification of response biomarkers

10 :45-11 :15 Coffee break & Exhibition - End of poster Session 2

11 :15-12 :15 General discussion Animated by Momo Bentires-Alj, Steven de Jong & Jos Jonkers

12 :15 Best poster prizes 10' Momo Bentires-Alj

12 :25 Closing remarks 10' Jos Jonkers

12 :35-14 :00 Buffet lunch & Departure

Sponsored by

15

www.europdx.eu www.europdxworkshop2016.eu Des

ign

ed b

y H

ugg

gy